# A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

> **NCT04300556** · PHASE1,PHASE2 · RECRUITING · sponsor: **Eisai Inc.** · enrollment: 182 (estimated)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** Farletuzumab ecteribulin
- **DRUG:** Prednisone
- **DRUG:** Prednisolone
- **DRUG:** Dexamethasone
- **DRUG:** Lenvatinib

## Key facts

- **NCT ID:** NCT04300556
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-08-06
- **Primary completion:** 2030-08-08
- **Final completion:** 2030-08-08
- **Target enrollment:** 182 (ESTIMATED)
- **Last updated:** 2026-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04300556

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04300556, "A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT04300556. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*